

ORGENTEC Diagnostika GmbH

Carl-Zeiss-Straße 49
55129 Mainz - Germany

Phone: +496131/92580
Fax: +496131/925858
Internet : www.orgentec.com



Instruction for use
August 2005



ORG 555 ThromboCombo IgG/IgM

Immunometric Enzyme Immunoassay for the simultaneous quantitative determination of IgG and IgM class antibodies against β 2-Glycoprotein I, Cardiolipin, Phosphatidyl Serine, Phosphatidyl Inositol and Phosphatidic Acid

CONTENTS

NAME AND INTENDED USE
SUMMARY AND EXPLANATION OF THE TEST
PRINCIPLE OF THE TEST
WARNINGS AND PRECAUTIONS
CONTENTS OF THE KIT
STORAGE AND STABILITY
MATERIALS REQUIRED
SPECIMEN COLLECTION AND HANDLING
PROCEDURAL NOTES
PREPARATION OF REAGENTS
TEST PROCEDURE
INTERPRETATION OF RESULTS
PERFORMANCE CHARACTERISTICS
LIMITATIONS OF PROCEDURE
INTERFERING SUBSTANCES
REFERENCES
INCUBATION SCHEME

NAME AND INTENDED USE

The ORGENTEC ThromboCombo IgG/IgM assay is a quantitative enzyme immunoassay (EIA) intended to screen for the presence of IgG and IgM class autoantibodies against β 2-Glycoprotein I, Cardiolipin, Phosphatidyl Serine, Phosphatidyl Inositol and Phosphatidic acid in human serum or plasma as an aid in the diagnosis of an increased risk of thrombosis in patients with Systemic Lupus Erythematosus (SLE) or lupus-like disorders.

SUMMARY AND EXPLANATION OF THE TEST

The first study of antiphospholipid antibodies began in 1906, when Wasserman introduced a serological test for Syphilis. In 1942, the active component was found to be a phospholipid, which was designated Cardiolipin. In the 1950s it became clear that a number of people had positive tests for syphilis without any evidence of the disease. This phenomenon was referred to as the biological false positive serological test for syphilis. A high prevalence of autoimmune disorders, including systemic lupus erythematosus (SLE) and Sjögrens Syndrome occurred in this group of patients.

The presence of circulating anti-coagulants in patients with SLE was first documented in 1952 and was associated with increased risk of paradoxical Thrombosis in 1963. The term Lupus anticoagulant (LA) was first used in 1972, is clearly a misnomer, because LA is more frequently encountered in patients without lupus and is associated with thrombosis rather than abnormal bleeding.

During the last years it became clear that the optimal binding of anti phospholipid antibodies is depending on a co-factor termed β 2-Glycoprotein I (apolipoprotein H) (GPI). GPI is a 50 kDa β 2-globulin occurring in plasma at a level of 200 μ g/ml. It has been found that β 2-Glycoprotein I (β 2GPI) inhibits the intrinsic coagulation pathway and, therefore, it is involved in the regulation of blood coagulation. β 2GPI is associated in vivo with negatively-charged substances, e.g. anionic phospholipids, heparin and lipo-proteins. The phospholipid binding region is located on its fifth domain.

Under the acronym "aPL" (anti-Phospholipid antibodies) antibodies against negatively charged phospholipids, such as CL (Cardiolipin), LA (Lupus Anticoagulant), PS (Phosphatidylserine), PI (Phosphatidylinositol) and PA (Phosphatidic Acid) are summarised. Of these, CL is the phospholipid most commonly used as antigen to test for aPL by ELISA. Some antisera which bind cardiolipin-coated ELISA plates can also bind plates coated with other negatively charged phospholipids, such as phosphatidylserine (PS) and phosphatidic acid (PA).

Some investigators have suggested that the use of PS in place of cardiolipin in ELISA tests enables more specific diagnosis. These antigens are less commonly used and their additional use can improve the clinical sensitivity in patient samples with suspected APS (Anti-Phospholipid-Syndrome), but at this time it seems that they can't replace the measurement of autoantibodies against Cardiolipin. To find out more about the different clinical relevance of the different phospholipid autoantibodies, we designed the ThromboCombo test system.

PRINCIPLE OF THE TEST

Highly purified Cardiolipin, Phosphatidyl Serine, Phosphatidyl Inositol, Phosphatidic Acid and human β 2-Glycoprotein I are bound to microwells. Antibodies against these antigens, if pre-

sent in diluted serum or plasma, bind to the respective antigens. Washing of the microwells removes unspecific serum and plasma components. Horseradish peroxidase (HRP) conjugated anti-human IgG and IgM immunologically detects the bound patient antibodies forming a conjugate/antibody/antigen complex. Washing of the microwells removes unbound conjugate. An enzyme substrate in the presence of bound conjugate hydrolyzes to form a blue color. The addition of an acid stops the reaction forming a yellow end-product. The intensity of this yellow color is measured photometrically at 450nm.

WARNINGS AND PRECAUTIONS

1. All reagents of this kit are strictly intended for in vitro diagnostic use only.
2. Do not interchange kit components from different lots.
3. Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
4. Avoid contact with the TMB (3,3',5,5'-Tetramethyl-benzidine). If TMB comes into contact with skin, wash thoroughly with water and soap.
5. Avoid contact with the Stop Solution which is hydrochloric acid (1 M). If it comes into contact with skin, wash thoroughly with water and seek medical attention.
6. Some kit components (i.e. Controls, Sample buffer and Buffered Wash Solution) contain Sodium Azide as preservative. Sodium Azide (NaN₃) is highly toxic and reactive in pure form. At the product concentrations (0.09%), though not hazardous. Despite the classification as non-hazardous, we strongly recommend using prudent laboratory practices (see 8., 9., 10.).
7. Some kit components contain Proclin 300 as preservative. When disposing reagents containing Proclin 300, flush drains with copious amounts of water to dilute the components below active levels.
8. Wear disposable gloves while handling specimens or kit reagents and wash hands thoroughly afterwards.
9. Do not pipette by mouth.
10. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled.
11. Avoid contact between the buffered Peroxide Solution and easily oxidized materials; extreme temperature may initiate spontaneous combustion.

Observe the guidelines for performing quality control in medical laboratories by assaying controls and/or pooled sera. During handling of all kit reagents, controls and serum samples observe the existing legal regulations.

CONTENTS OF THE KIT

Package size 96 determ. / 12 profiles
 Qty.1 divisible microplate consisting of 12 modules of 8 wells, coated with:

Row A: Reference Antigen
 Row B: β2-Glycoprotein I (β2-GP I)
 Row C: Cardioliipin (with β2-GP I)
 Row D: Phosphatidyl Serine (with β2-GP I)
 Row E: Phosphatidyl Inositol (with β2-GP I)
 Row F: Phosphatidic Acid (with β2-GP I)
 Row G: Mixed antigen: see coating row C-F (with β2-GP I)
 Row H: Mixed antigen: see coating row C-F (without β2-GP I). Ready to use.

6 vials, 1.5 ml each Combined Anti-phospholipid calibrators in a serum/buffer matrix (PBS, NaN₃ <0,1% (w/w)) containing IgG: 0; 6.3; 12.5; 25; 50; 100 U/ml and IgM: 0; 6.3; 12.5; 25; 50; 100 U/ml. Ready to use.

1 vial, 20 ml Sample buffer (Tris, NaN₃ <0,1% (w/w)), yellow, concentrate (5x).

1 vial, 15 ml Enzyme conjugate solution (PBS, PROCLIN 300 <0,5% (v/v)), (light red) containing polyclonal rabbit anti-human IgG; labelled with horseradish peroxidase. Ready to use.

1 vial, 15 ml Enzyme conjugate solution (PBS, PROCLIN 300 <0,5% (v/v)), (light red) containing polyclonal rabbit anti-human IgM; labelled with horseradish peroxidase. Ready to use.

1 vial, 15 ml TMB substrate solution. Ready to use.

1 vial, 15 ml Stop solution (1 M hydrochloric acid). Ready to use.

1 vial, 20 ml Wash solution (PBS, NaN₃ <0,1% (w/w)), concentrate (50x).

STORAGE AND STABILITY

1. Store the kit at 2-8 °C.
2. Keep microplate wells sealed in a dry bag with desiccants.
3. The reagents are stable until expiration of the kit.
4. Do not expose test reagents to heat, sun or strong light during storage and usage.
5. Diluted sample buffer and wash buffer are stable for at least 30 days when stored at 2-8 °C.

MATERIALS REQUIRED

Equipment

- Microplate reader capable of endpoint measurements at 450 nm
- Multi-Channel Dispenser or repeatable pipet for 100 µl
- Vortex mixer
- Pipets for 10 µl, 100 µl and 1000 µl
- Laboratory timing device
- Data reduction software

Preparation of reagents

- Distilled or deionized water
- Graduated cylinder for 100 and 1000 ml
- Plastic container for storage of the wash solution

SPECIMEN COLLECTION, STORAGE AND HANDLING

1. Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
2. Allow blood to clot and separate the serum by centrifugation.
3. Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia is best avoided, but does not interfere with this assay.
4. Specimens may be refrigerated at 2-8 °C for up to five days or stored at -20 °C up to six months.
5. Avoid repetitive freezing and thawing of serum samples. This may result in variable loss of autoantibody activity.
6. Testing of heat-inactivated sera is not recommended.

PROCEDURAL NOTES

1. Do not use kit components beyond their expiration dates.
2. Do not interchange kit components from different lots.
3. All materials must be at room temperature (20-28 °C).
4. Have all reagents and samples ready before start of the assay. Once started, the test must be performed without interruption to get the most reliable and consistent results.
5. Perform the assay steps only in the order indicated.
6. Always use fresh sample dilutions.
7. Pipette all reagents and samples into the bottom of the wells.
8. To avoid carryover contamination change the tip between samples and different kit controls.
9. It is important to wash microwells thoroughly and remove the last droplets of wash buffer to achieve best results.
10. All incubation steps must be accurately timed.
11. Control sera or pools should routinely be assayed as unknowns to check performance of the reagents and the assay.
12. Do not re-use microplate wells.

For all controls, the respective concentrations are provided on the labels of each vial. Using these concentrations a calibration curve may be calculated to read off the patient results semi-quantitatively.

PREPARATION OF REAGENTS

Preparation of sample buffer

Dilute the contents of each vial of the sample buffer concentrate (5x) with distilled or deionized water to a final volume of 100 ml prior to use. Store refrigerated: stable at 2-8 °C for at least 30 days after preparation or until the expiration date printed on the label.

Preparation of wash solution

Dilute the contents of each vial of the buffered wash solution concentrate (50x) with distilled or deionized water to a final volume of 1000 ml prior to use. Store refrigerated: stable at 2-8 °C for at least 30 days after preparation or until the expiration date printed on the label.

Sample preparation

Dilute all patient samples 1:101 with sample buffer before assay. Therefore combine 10 µl of sample with 1000 µl of sample buffer in a polystyrene tube. Mix well. Controls are ready to use and need not be diluted.

TEST PROCEDURE

Assay layout

- Row A The wells of row A are coated with a reference antigen and serve to perform the standard curve.
- Row B The wells are coated with β2-Glycoprotein I.
- Row C The wells are coated with Cardiolipin (plus β2-Glycoprotein I).
- Row D The wells are coated with Phosphatidyl Serine (plus β2-Glycoprotein I).
- Row E The wells are coated with Phosphatidyl Inositol (plus β2-Glycoprotein I).
- Row F The wells are coated with Phosphatidic Acid (plus β2-Glycoprotein I).
- Row G The wells are coated with a mixture of Cardiolipin, Phosphatidyl Serine, Phosphatidyl Inositol and Phosphatidic Acid (plus β2-Glycoprotein I).
- Row H The wells are coated with a mixture of Cardiolipin, Phosphatidyl Serine, Phosphatidyl Inositol and Phosphatidic Acid (β2-Glycoprotein I).

Procedure

1. Prepare a sufficient number of microplate modules to accommodate controls and prediluted patient samples.
2. For the determination of one class of autoantibodies pipette **100 µl** of calibrators and **7 x 100 µl** prediluted patient samples into the wells.
For determination of both IgG and IgM autoantibodies calibrators and patient samples have to be pipetted in two attempts.

	1	2	3	4	5	6	7	8	9	10	11	12
A - Reference antigen	SA	SB	SC	SD	SE	SF	SA	SB	SC	SD	SE	SF
B - β2-Glycoprotein	P1	P2	P3	P4	P5	P6	P1	P2	P3	P4	P5	P6
C - Cardiolipin & β2-Glycoprotein	P1	P2	P3	P4	P5	P6	P1	P2	P3	P4	P5	P6
D - Phosphatidylserin & β2-Glycoprotein	P1	P2	P3	P4	P5	P6	P1	P2	P3	P4	P5	P6
E - Phosphatidylinositol & β2-Glycoprotein	P1	P2	P3	P4	P5	P6	P1	P2	P3	P4	P5	P6
F - Phosphatidic Acid & β2-Glycoprotein	P1	P2	P3	P4	P5	P6	P1	P2	P3	P4	P5	P6
G - Mixture row C/D/E/F & β2-Glycoprotein	P1	P2	P3	P4	P5	P6	P1	P2	P3	P4	P5	P6
H - Mixture row C/D/E/F without β2-Glycoprotein	P1	P2	P3	P4	P5	P6	P1	P2	P3	P4	P5	P6

SA, SB...SF Calibrators A to F P1,P2... Patient Samples 1,2,...

3. Incubate for 30 minutes at room temperature (20-28 °C).
4. Discard the contents of the microwells and wash 3 times with **300 μ l** of wash solution.
5. Dispense **100 μ l** of enzyme conjugate (Anti-h-IgG or Anti-h-IgM) into each well.
6. Incubate for 15 minutes at room temperature.
7. Discard the contents of the microwells and wash 3 times with **300 μ l** of wash solution.
8. Dispense **100 μ l** of TMB substrate solution into each well.
9. Incubate for 15 minutes at room temperature.
10. Add **100 μ l** of stop solution to each well of the modules and incubate for 5 minutes at room temperature.
11. Read the optical density at 450 nm and calculate the results. Bi-chromatic measurement with a reference at 600-690 nm is recommended.

The developed colour is stable for at least 30 minutes. Read optical densities during this time.

INTERPRETATION OF RESULTS

Quality Control

This test is only valid if the optical density at 450 nm for standard A and standard F complies with the respective range indicated on the Quality Control Certificate enclosed to each test kit ! If any of these criteria is not fulfilled, the results are invalid and the test should be repeated.

Calculation of results

For the ThromboCombo test a 4-Parameter-Fit with lin-log co-ordinates for optical density and concentration is the data reduction method of choice.

Recommended Lin-Log Plot

First calculate the averaged optical densities for each calibrator well. Use lin-log graph paper

and plot the averaged optical density of each calibrator versus the concentration. Draw the best fitting curve approximating the path of all calibrator points. The calibrator points may also be connected with straight line segments. The concentration of unknowns may then be estimated from the calibration curve by interpolation.

Interpretation of results

In a normal range study with serum samples from healthy blood donors the following ranges have been established with the ThromboCombo test:

	IgG [U/ml]	IgM [U/ml]
normal:	< 10	< 10
elevated:	≥ 10	≥ 10

It is recommended that each laboratory establishes its own normal and pathological ranges. The values should be regarded as guidelines only.

PERFORMANCE CHARACTERISTICS

Parallelism

In dilution experiments sera with high antibody concentrations were diluted with sample buffer and assayed in the ThromboCombo kit. The assay shows linearity over the full measuring range.

Specificity

The microplate is coated with highly purified Cardiolipin, Phosphatidyl Serine, Phosphatidyl Inositol, Phosphatidic Acid, a mixture of these phospholipids and human β 2-Glycoprotein I. Special coating processes, developed by the manufacturer guarantee the native immunogenic structure of the phospholipids after immobilisation on the solid phase. The ELISA kit is specific for autoantibodies directed against the respective phospholipid or the complex of the negatively-charged phospholipid and β 2-Glycoprotein I. No cross-reactivity was observed to anti-DNA antibodies and those types of antibodies occurring in Syphilis.

Calibration

The assay system is calibrated against the internationally recognised reference sera from E.N. Harris, Louisville, since no other international standards are available.

LIMITATIONS OF PROCEDURE

The ThromboCombo IgG/IgM ELISA is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but should be made by the physician after all clinical and laboratory findings have been evaluated.

INTERFERING SUBSTANCES

No interference has been observed with haemolytic (up to 1000 mg/dL), lipemic (up to 3 g/dL triglycerides) or bilirubin (up to 40 mg/dL) containing sera. Nor have any interfering effects

been observed with the use of anticoagulants. However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

REFERENCES

1. Hughes, G.R.V., Harris, E.N. and Gharavi, A.E. The Anticardiolipin Syndrome. *J. Rheumat.* 1986; 13, 3: 486 - 489.
2. Harris, E.N. et al. Evaluation of the anti-Cardiolipin antibody test: report of an International Workshop held 4 April 1986. *Clin. Exp. Immunol.* 1987; 68: 215 - 222.
3. Domke, N. and Siegert, G. Phospholipidantikörper und ihre klinische Bedeutung. *Zeitschrift für Klinische Medizin* 1988; Heft 16: 1399 - 1401.
4. Pengo, V. et al. Immunological Specificity and Mechanism of Action of IgG Lupus Anticoagulants. *Blood* 1987; Vol 70, No 1: 69 - 76.
5. Triplett, D.A. Coagulation Assays for the Lupus Anticoagulant: Review and Critique of Current Methodology. *Stroke* 1992; Vol 23, No 2 [suppl I]: I-11 - I-14.
6. Harris, E.N. Serological Detection of Antiphospholipid Antibodies. *Stroke* 1992; Vol 23, No 2 [suppl I]: I-3 - I-6.
7. Eilat, D. et al. Evaluation of cross-reaction between anti-DNA and anti-Cardiolipin antibodies in SLE and experimental animals. *Clin. Exp. Immunol.* 1986; 65: 269 - 278.
8. Matsuda, J. et al. Detection of Beta-2-Glycoprotein-I-Dependent Antiphospholipid Antibodies and Anti-Beta-2-Glycoprotein-I Antibody in Patients with Systemic Lupus Erythematosus and in Patients with Syphilis. *Int. Arch. Allergy Immunol.* 1994; 103: 239 - 244.
9. Kalunian, K.C. et al. Clinical Significance of a Single Test for Anti-Cardiolipin Antibodies in Patients with Systemic Lupus Erythematosus. *Am. J. Med.* 1988; Vol 85: 602 - 608.
10. Al-Momen, A.-K. et al. IgA Antiphospholipid and Adrenal Insufficiency: Is there a link? *Thromb. Res.* 1991; Vol 64, No 5: 571 - 578.

INCUBATION SCHEME

